TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25771069
Drug: Enalapril and
Normalized name: enalapril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril and folic acid (10 mg enalapril, 0.8 mg folic acid)
Study: 25771069
Drug: Enalapril alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril alone (10 mg)
Study: 23585557
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality (VR) exposure therapy, n = 7
Study: 23585557
Drug: Imaginal Exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imaginal Exposure (IE) therapy, n = 8
Study: 18795264
Drug: Naltrexone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone treatment with cognitive behavioral therapy
Study: 1694236
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine and daunorubicin (course one) followed by standard-dose cytarabine and daunorubicin (course two)
Study: 1694236
Drug: Azacitidine and
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine and doxorubicin (course one) followed by standard-dose cytarabine, daunorubicin, and thioguanine (course two)
Study: 1694236
Drug: High-dose cytarabine-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine-based chemotherapy and/or allogeneic bone marrow transplantation (BMT)
Study: 1694236
Drug: ALP3 postremission
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALP3 postremission chemotherapy regimen
Study: 619938
Drug: Glycopyrronium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium 0.2 mg intramuscularly
Study: 619938
Drug: Glycopyrronium (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium (oral route)
Study: 619938
Drug: Glycopyrronium (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium (intravenous route)
Study: 619938
Drug: Glycopyrronium (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium (intramuscular route)
Study: 619938
Drug: Larger doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larger doses of Glycopyrronium
Study: 29468701
Drug: 50 mg/d
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/d allopurinol
Study: 29468701
Drug: 100 mg/d
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/d allopurinol
Study: 24418037
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (n = 50)
Study: 20497967
Drug: Matuzumab plus
Normalized name: Matuzumab
DrugBank: Matuzumab (DB05101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matuzumab plus ECX (800 mg matuzumab weekly, epirubicin 50 mg/m², cisplatin 60 mg/m², capecitabine 1250 mg/m²)
Study: 20497967
Drug: ECX alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECX alone (epirubicin 50 mg/m², cisplatin 60 mg/m², capecitabine 1250 mg/m²)
Study: 18456138
Drug: Implant group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant group
Study: 12448067
Drug: Atenolol (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (n = 28; dose 25 to 100 mg)
Study: 12448067
Drug: Terazosin (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (n = 26; dose 1 to 10 mg)
Study: 9607387
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 to 10 mg once daily (n = 55)
Study: 9607387
Drug: Nifedipine SR
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine SR 20 mg twice daily (n = 48)
Study: 7883543
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg enoxaparin administered 12 hours before surgery
Study: 7883543
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 12 hours before surgery
Study: 2244403
Drug: Flurbiprofen 50
Normalized name: flurbiprofen 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 50 mg tid
Study: 402206
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment methods (inguinal orchiectomy with irradiation and pre- and postoperative irradiation with lymphadenectomy)
Study: 28467880
Drug: Teprotumumab (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teprotumumab (administered intravenously once every 3 weeks for a total of eight infusions)
Study: 28467880
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered intravenously once every 3 weeks for a total of eight infusions)
Study: 22805083
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine group (CMG) - treated with Chinese medicine according to syndrome differentiation for 48 weeks.
Study: 22805083
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine group (WMG) - treated with donepezil at a dose of 5 mg once daily for 48 weeks.
Study: 19910654
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA (2.4 g/d; 2,000 mg EPA, 400 mg DHA)
Study: 31018727
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (NPWT) using PICO, Smith & Nephew, St. Petersburg, FL
Study: 31018727
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (NPWT) using PICO, Smith & Nephew, St. Petersburg, FL (after matching)
Study: 30064450
Drug: Betaine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaine (2.5 g/day)
Study: 26937942
Drug: N2O (nitrous
Approvals — FDA: no, EMA: no, PMDA: no
Description: N2O (nitrous oxide) inhalation
Study: 23345635
Drug: Rivastigmine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine (up to 12 mg/day for 20 weeks)
Study: 19707287
Drug: Anticoagulant and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant and antiplatelet agents (specific agents not detailed)
Study: 15566681
Drug: EMBE and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMBE and after-loading treatment
Study: 8322572
Drug: Propofol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.5 mg.kg‐1
Study: 8322572
Drug: Methohexitone 2
Normalized name: Methohexitone
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methohexitone 2 mg.kg‐1
Study: 8322572
Drug: Propofol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.5 and 2.5 mg.kg‐1
Study: 3709070
Drug: Topical anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthesia of the upper airways
Study: 31566918
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral treatment for childhood insomnia (CBT‐CI)
Study: 29772190
Drug: Dental implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental implant placement
Study: 22934396
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (Nifedipine tablets 20 mg orally in the morning)
Study: 18376092
Drug: Intermittent methylene
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent methylene blue therapy (Gr I, n=5)
Study: 18376092
Drug: Continuous methylene
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous methylene blue therapy (Gr II, n=6)
Study: 7024868
Drug: Azatadine maleate
Normalized name: Azatadine Maleate
DrugBank: Azatadine (DB00719)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azatadine maleate (Zadine) 2 mg twice daily
Study: 7024868
Drug: Azatadine maleate
Normalized name: Azatadine Maleate
DrugBank: Azatadine (DB00719)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azatadine maleate (Zadine) 1 mg twice daily
Study: 30040589
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (CBT) for sexual dysfunction
Study: 20860913
Drug: Golimumab 50
Normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab 50 mg every 4 weeks
Study: 26416942
Drug: Topical and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical and intraurethral 2% lidocaine gel
Study: 24211510
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg daily) for 28 days
Study: 22475140
Drug: Telbivudine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine (600 mg/d until postpartum week 4)
Study: 19881322
Drug: Continuous passive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous passive motion (CPM) started on the first postoperative day with conventional physical therapy (n=29)
Study: 19881322
Drug: Continuous passive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous passive motion (CPM) started on the third postoperative day with conventional physical therapy (n=29)
Study: 19881322
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy only (control group, n=28)
Study: 11343232
Drug: Butyl cyanoacrylate
Normalized name: N-butyl cyanoacrylate
DrugBank: Enbucrilate (DB12358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butyl cyanoacrylate injection (group A)
Study: 3297595
Drug: verapamil 120
Normalized name: verapamil 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 120 mg three times daily
Study: 28292551
Drug: Continuous paravertebral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous paravertebral block at levels T1 and T2 with bupivacaine infusion
Study: 23299960
Drug: Nebulised magnesium
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised magnesium sulphate (151 mg per dose)
Study: 17100370
Drug: 0.025 mg/d
Normalized name: estradiol 0.025 MG/Day Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025 mg/d transdermal estradiol
Study: 17100370
Drug: 0.05 mg/d
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/d transdermal estradiol
Study: 15119922
Drug: Olanzapine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (up to 20 mg/day)
Study: 11231440
Drug: ANP (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANP (30 ng/kg/min) infusion before and after ACEi treatment (n = 9)
Study: 11231440
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of ANP with acute saline solution load (n = 8)
Study: 11231440
Drug: Acute saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute saline solution loading (n = 8)
Study: 9566811
Drug: Physostigmine (maximal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (maximal tolerated dose)
Study: 4400530
Drug: M &
Normalized name: Publix Calcium & D Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: M & B 17803A (300 mg)
Study: 4400530
Drug: Propranolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (10 and 40 mg)
Study: 4400530
Drug: M &
Normalized name: Publix Calcium & D Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: M & B 17803A (small oral doses)
Study: 31371154
Drug: Topical haemostatic
Normalized name: collagen hemostat Topical Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical haemostatic agents (oxidized cellulose or collagen) + fibrin glue (experimental group with VADs)
Study: 31371154
Drug: Topical haemostatic
Normalized name: collagen hemostat Topical Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical haemostatic agents (oxidized cellulose or collagen) (control group)
Study: 26043724
Drug: AZD9668 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9668 60 mg twice daily (BID)
Study: 26043724
Drug: AZD9668 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9668 60 mg BID
Study: 23704939
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg apomorphine
Study: 18953498
Drug: Antihypertensive agent
Normalized name: Antihypertensive agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive agent (parenteral or oral)
Study: 18953498
Drug: Both IV
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both IV MgSO(4) and antihypertensive agent
Study: 3132034
Drug: Zinc supplement
Normalized name: Zinc supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplement of 50 mg daily for 2 weeks
Study: 3132034
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no zinc supplement)
Study: 18269927
Drug: Omalizumab 0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab 0.015 mg/kg/IU/mL every 2 weeks for 28 weeks
Study: 18269927
Drug: Omalizumab 0.030
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab 0.030 mg/kg/IU/mL every 2 weeks for 28 weeks
Study: 18269927
Drug: Reduced doses
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced doses of omalizumab (0.0015 or 0.0050 mg/kg/IU/mL every 2 weeks for 18 weeks)
Study: 18269927
Drug: Complete discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete discontinuation of omalizumab therapy
Study: 12850599
Drug: Advance provision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advance provision of emergency contraception (8 oral contraceptive pills containing 0.15 mg of levonorgestrel and 30 microg of ethinyl estradiol) and a 5-minute educational session
Study: 7484285
Drug: Alendronate 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 2.5 mg
Study: 2271372
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (8 g)
Study: 14585761
Drug: LIPC‐480 CC/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIPC‐480 CC/CT genotype with normal physical activity (reference group)
Study: 11056771
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (nodraparin calcium, Fraxiparine) administered according to body weight
Study: 1457788
Drug: Manganese DPDP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manganese DPDP (5 mumol/kg, 10 mumol/ml concentration)
Study: 31282364
Drug: Subcutaneous liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous liraglutide
Study: 23002259
Drug: 10 mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg, 0.5% hyperbaric bupivacaine with the Whitacre needle oriented laterally
Study: 23002259
Drug: 10 mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg, 0.5% hyperbaric bupivacaine with the Whitacre needle oriented cephalad
Study: 15676041
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oral artemisinin daily for 5 days
Study: 15676041
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of 100/100/250/250/500 mg on each of the first 5 days
Study: 10359405
Drug: Budesonide 800
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 800 microg plus 400 microg daily for 6 months followed by 400 microg twice daily for 30 months
Study: 2127335
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg vancomycin administered into the ventricular system during surgery
Study: 31006038
Drug: Sunitinib 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 15 mg/m2 per day, 4-weeks-on/2-weeks-off (schedule 4/2), with intra-patient dose escalation to 22.5 and subsequently 30 mg/m2 based on tolerability.
Study: 30061768
Drug: Nanosil mouthwash
Normalized name: Nanosilver
DrugBank: Silver (DB12965)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanosil mouthwash (oral decontamination program performed three times a day for five days)
Study: 30061768
Drug: Chlorhexidine 0.12%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine 0.12% (oral decontamination program performed three times a day for five days)
Study: 19884037
Drug: Cervical spine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical spine manual therapy (lateral glide)
Study: 17335465
Drug: Lamotrigine 25
Normalized name: lamotrigine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine 25 mg twice daily
Study: 17335465
Drug: Amitriptyline 10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 10, 25, and 50 mg at night-time
Study: 17335465
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Lamotrigine and Amitriptyline)
Study: 10344555
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy (Mitoxantrone: 45 mg/m2, Cyclophosphamide: 120 mg/kg, Melphalan: 140 mg/m2)
Study: 10344555
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (conventional chemotherapy)
Study: 1758944
Drug: Support therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Support therapy
Study: 26577683
Drug: Twice-daily budesonide
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily budesonide 2mg foam
Study: 24480430
Drug: PBSC group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBSC group received subcutaneous G-CSF injections (15 µg/kg/day) for 5 consecutive days, followed by stereotaxic implantation of 3-8 × 10(6) CD34(+) immunosorted PBSCs.
Study: 17598500
Drug: Comprehensive, population-based,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive, population-based, organised cervical cancer prevention programmes integrating cervical screening with new technologies and vaccines
Study: 15768872
Drug: Qingxin capsule
Normalized name: SILICON DIOXIDE 14 g in 100 g / .ALPHA.-TOCOPHEROL ACETATE 0.1 g in 100 g / SODIUM PYROPHOSPHATE 0.5 g in 100 g DENTAL PASTE, DENTIFRICE [Mastikis Qingxin Care Mastic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingxin capsule (QXC)
Study: 9505778
Drug: Pirenzepine 25
Normalized name: pirenzepine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 25 mg + Ranitidine 75 mg
Study: 343743
Drug: Naproxen 250
Normalized name: naproxen 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 250 mg twice a day
Study: 343743
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg taken at bedtime
Study: 11755835
Drug: Indomethacin 25
Normalized name: indomethacin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 25 mg four times a day
Study: 343743
Drug: Naproxen (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (single daily dose)
Study: 17356963
Drug: Medication databases
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication databases
Study: 15687448
Drug: PI-containing combination
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PI-containing combination therapy
Study: 12351435
Drug: Troglitazone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (600 mg/day) for 3 months
Study: 10072479
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg thioctic acid (TA)
Study: 10072479
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg thioctic acid (TA)
Study: 7552589
Drug: Carbohydrate intake
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate intake of 8 g/kg/day (5.5 mg/kg/minute)
Study: 7552589
Drug: Carbohydrate intake
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate intake of 12 g/kg/day (8.3 mg/kg/minute)
Study: 31464626
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (TCM) integrated treatment program including tripterygium glycosides (TGs), tanshinone IIa sodium sulfonate injection, and Chinese herbs based on syndrome differentiation
Study: 31464626
Drug: Benazepril hydrochloride
Normalized name: Benazepril Hydrochloride
DrugBank: Benazepril (DB00542)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benazepril hydrochloride tablets, low molecular weight heparin calcium injection, dipyridamole tablets, and a Chinese medicine placebo
Study: 31464626
Drug: Benazepril hydrochloride
Normalized name: Benazepril Hydrochloride
DrugBank: Benazepril (DB00542)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benazepril hydrochloride tablets, low molecular weight heparin calcium injection, dipyridamole tablets, a Chinese medicine placebo, and prednisone
Study: 25244414
Drug: Probiotic therapy
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic therapy (Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus rhamnosus, and Streptococcus thermophilus) for 4 weeks
Study: 12040670
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy plus surgical salvage treatment
Study: 22392456
Drug: Citalopram (first-step
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (first-step treatment)
Study: 22392456
Drug: Sustained-release bupropion,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release bupropion, sertraline, or extended-release venlafaxine (second-step treatment)
Study: 93297
Drug: gamma-globulin 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: gamma-globulin 16 Merieux (1 ml/kg)
Study: 31118057
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) at 4 J/cm2